Here is a brief review of stocks to watch with potential ASCO impact although it is likely that prices already reflect the scientific news:
Ariad Pharmaceuticals Inc. (ARIA $8.43) up 0.36% will present Phase III data on ponatinab, its investigational pan-BCR-ABL and ridaforolimus an mTOR inhibitor both with multiple indications.An investor presentation will be held on June 6 after the scientific sessions.
Dendreon Corp. (DNDN $41.91) up 2.54%, will have four presentations on Provenge (sipuleucel-T) immunotherapy data with patients being treated for hormone refractory prostate cancer.FDA approved the product in April 2010.
Endocyte, Inc. (ECYT $11.80) N/C , a biopharmaceutical Company developing small molecule drug conjugates (SMDC’s) and companion imaging diagnostics for personalized therapy will present final progression free survival data(PFS) on June 5 from the Phase 2 PRECEDENT clinical trial of EC 145 in women with platinum-resistant ovarian cancer. The Company raised $75M in an IPO on February 4 and the stocks is up 70% as of today.
Exelixis, Inc. (EXEL $11.17) up 2% will present Phase II data on June 4,5,and 6th on XL184 (cabozatinib) for a variety of cancer indications including prostate cancer.
Aside from ASCO
Our index of mid-cap biopharmaceutical stocks was active and bullish today with six stocks down and 27 up. Cubist (CBST $38.30) was up another 4% presumably due to takeover rumors with Shire in the picture. The Optimer (OPTR $13.99) PDUFA is approaching on May 30 for fidaxomycin to treat C.difficile infection.